ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
P/E ratio for ESSA Pharma Inc. (EPIX)
P/E ratio as of 2023: -5.13
According to ESSA Pharma Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.13. At the end of 2022 the company had a P/E ratio of -2.28.
P/E ratio history for ESSA Pharma Inc. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -5.13 |
| 2022 | -2.28 |
| 2021 | -8.36 |
| 2020 | -6.61 |
| 2019 | -2.72 |
| 2018 | -1.24 |
| 2017 | -1.88 |
| 2016 | -5.63 |
| 2015 | -13.52 |
| 2014 | -38.02 |
| 2013 | -50.54 |
| 2012 | -33.39 |